OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00252456

Guangzheng Eye Hospital Group Co Ltd

Healthcare Facilities & ServicesVerified

Guangzheng Eye Hospital Group Co Ltd has a highly leveraged capital structure, with a debt-to-equity ratio of 8.2, indicating significant reliance on debt financing. Despite reporting positive operating cash flow of CNY 124.7 million, the company’s free cash flow is only CNY 22.8 million, and its liquidity position is constrained by a current ratio of 0.35, suggesting limited short-term liquidity. The company’s profitability is weak, with a net loss of CNY 19.5 million and a negative return on equity of -20.35%, far below the typical performance of healthcare service providers. Gross profit of CNY 321 million represents 36.3% of revenue, but operating income is only CNY 4.24 million, indicating high operating expenses relative to revenue. The company’s revenue is concentrated in its domestic market, with no disclosed international operations. It operates in three primary segments: eye hospitals, energy, and steel structures. However, the financial data does not provide a breakdown of revenue by segment, limiting visibility into the performance of each business line. Looking ahead, the company’s revenue growth is uncertain. While it has maintained a positive operating cash flow, the net loss and weak return on assets (-1.65%) suggest ongoing operational challenges. The capital expenditure of CNY -29 million indicates some level of investment, but the scale is small relative to the company’s total assets. The company faces moderate liquidity risk due to its high debt load and low current ratio. The risk assessment flags a negative net cash position after subtracting total debt, which could constrain its ability to fund operations or invest in growth without external financing. The dilution risk is currently low, but the company’s equity base is small relative to its liabilities, which could increase dilution pressure in the event of a capital raise. Recent filings and transcripts do not provide specific details on strategic initiatives or major events. The company’s 10-K or equivalent disclosures would be necessary to assess management’s response to financial challenges and its plans for improving profitability.

30-day price · 002524-0.21 (-4.7%)
Low$3.99High$4.58Close$4.22As of15 May, 00:00 UTC
Profile
CompanyGuangzheng Eye Hospital Group Co Ltd
Ticker002524.SZ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Guangzheng Eye Hospital Group Co Ltd operates as a China-based provider of ophthalmological services through its network of specialized eye hospitals, and also engages in energy and steel structure businesses.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Guangzheng Eye Hospital Group Co Ltd has a highly leveraged capital structure, with a debt-to-equity ratio of 8.2, indicating significant reliance on debt financing. Despite reporting positive operating cash flow of CNY 124.7 million, the company’s free cash flow is only CNY 22.8 million, and its liquidity position is constrained by a current ratio of 0.35, suggesting limited short-term liquidity. The company’s profitability is weak, with a net loss of CNY 19.5 million and a negative return on equity of -20.35%, far below the typical performance of healthcare service providers. Gross profit of CNY 321 million represents 36.3% of revenue, but operating income is only CNY 4.24 million, indicating high operating expenses relative to revenue. The company’s revenue is concentrated in its domestic market, with no disclosed international operations. It operates in three primary segments: eye hospitals, energy, and steel structures. However, the financial data does not provide a breakdown of revenue by segment, limiting visibility into the performance of each business line. Looking ahead, the company’s revenue growth is uncertain. While it has maintained a positive operating cash flow, the net loss and weak return on assets (-1.65%) suggest ongoing operational challenges. The capital expenditure of CNY -29 million indicates some level of investment, but the scale is small relative to the company’s total assets. The company faces moderate liquidity risk due to its high debt load and low current ratio. The risk assessment flags a negative net cash position after subtracting total debt, which could constrain its ability to fund operations or invest in growth without external financing. The dilution risk is currently low, but the company’s equity base is small relative to its liabilities, which could increase dilution pressure in the event of a capital raise. Recent filings and transcripts do not provide specific details on strategic initiatives or major events. The company’s 10-K or equivalent disclosures would be necessary to assess management’s response to financial challenges and its plans for improving profitability.
Key takeaways
  • Guangzheng Eye Hospital Group Co Ltd is highly leveraged, with a debt-to-equity ratio of 8.2, indicating significant financial risk.
  • The company reported a net loss of CNY 19.5 million and a negative return on equity of -20.35%, reflecting poor profitability.
  • Operating cash flow is positive at CNY 124.7 million, but free cash flow is limited to CNY 22.8 million, constraining financial flexibility.
  • Revenue is concentrated in the domestic market, with no international operations disclosed.
  • The company’s liquidity position is weak, with a current ratio of 0.35 and a negative net cash position after debt.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$885.2M
Gross profit$321.0M
Operating income$4.2M
Net income-$19.5M
R&D
SG&A
D&A
SBC
Operating cash flow$124.7M
CapEx-$29.0M
Free cash flow$22.8M
Total assets$1.18B
Total liabilities$1.09B
Total equity$95.8M
Cash & equivalents
Long-term debt$785.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$95.8M
Net cash-$785.6M
Current ratio0.3
Debt/Equity8.2
ROA-1.7%
ROE-20.3%
Cash conversion-6.4%
CapEx/Revenue-3.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric002524Activity
Op margin0.5%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin-2.2%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin36.3%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-3.3%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity820.0%71.3% medp25 19.0% · p75 91.7%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 15:45 UTC#b6127828
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 15:47 UTCJob: 3d2413ac